Mechanisms of Deep Vein Thrombosis (DVT) and Vein Wall Fibrosis

Exclusion Criteria

• •Concurrent participation in another therapeutic clinical trial
• •History of prior DVT in the previous 2 years
• •Recurrent deep vein thrombosis (DVT)
• •Established post thrombotic syndrome (PTS)
• •Limb-threatening circulatory compromise
• •Pulmonary embolism with hemodynamic compromise
• •Deranged baseline coagulation profile before initiation of anticoagulation: INR \> 1.5 or aPTT prolonged \>40
• •Active bleeding within last 3 months
• •Anemia with Hemoglobin\<9 mg/dL
• •Thrombocytopenia with platelets \< 100,000/ml
• •Previously documented hypersensitivity to either the drug or excipients
• •Any contraindication to anticoagulation or allergy to factor V inhibitors or ferumoxytol
• •Any contraindication to magnetic resonance imaging (MRI) including metal implants or claustrophobia
• •Severe hepatic impairment as defined by Childs-Pugh Class B or C
• •Severe renal impairment with CrCl\<30 ml/min,
• •Taking any P-GP or strong CYP3A4 inhibitors or inducers
• •History of major bleeding including history of gastrointestinal bleeding or intracranial bleeding
• •Known history of bleeding diathesis
• •History of chronic atrial fibrillation or stroke
• •History of active cancer or malignancy within 1 year,
• •Life expectancy \<2 years.
• •Patients requiring emergent or urgent surgery or procedures within the first 3 months of the study that cannot be postponed will be excluded.
• •Patients who are breastfeeding or anticipate pregnancy
• •Participant is pregnant or breastfeeding
• •Participant is a prisoner (protected population)